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Abstract
Microgravity has been shown to influence the expression of ABC (ATP-Binding
Cassette) transporters in bacteria, fungi and mammals, but also to modify the
activity of certain cellular components with structural and functional similarities
to ABC transporters. Changes in activity of ABC transporters could lead to
important metabolic disorders and undesired pharmacological effects during
spaceflights. However, no current means exist to study the functionality of
these transporters in microgravity. To this end, a Vesicular Transport Assay
(Solvo Biotechnology, Hungary) was adapted to evaluate multi-drug
resistance-associated protein 2 (MRP2) trans-membrane
estradiol-17-β-glucuronide (E17βG) transport activity, when activated by
adenosine-tri-phosphate (ATP) during parabolic flights. Simple diffusion,
ATP-independent transport and benzbromarone inhibition were also evaluated.
A high accuracy engineering system was designed to perform, monitor and
synchronize all procedures. Samples were analysed using a validated high
sensitivity drug detection protocol. Experiments were performed in microgravity
during parabolic flights, and compared to 1g on ground results using identical
equipment and procedures in all cases. Our results revealed that sufficient
equipment accuracy and analytical sensitivity were reached to detect transport
activity in both gravitational conditions. Additionally, transport activity levels of
on ground samples were within commercial transport standards, proving the
validity of the methods and equipment used. MRP2 net transport activity was
significantly reduced in microgravity, so was signal detected in simple diffusion
samples. Ultra-structural changes induced by gravitational stress upon vesicle
membranes or transporters could explain the current results, although
alternative explanations are possible. Further research is needed to provide a
conclusive answer in this regard. Nevertheless, the present validated
technology opens new and interesting research lines in biology and human
physiology with the potential for significant benefits for both space and
terrestrial medicine.
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Introduction
Critical medical situations can occur in space missions1. In such 
situations, adequate treatment may require the use of drugs with 
potential severe side effects. Pharmacokinetics and pharmacody-
namics can be modified under weightlessness conditions by many 
factors2,3, which may lead to undesired pharmacological effects. 
These parameters should be assessed carefully in order to ensure 
safe use of medications in space. However, insufficient information 
exists in this regard in microgravity4,5 and proper empirical evalua-
tion is not feasible due to the significant associated risks.
ABC (ATP-Binding Cassette) transporters are a large family of 
trans-membrane proteins widely present in many life forms, from 
bacteria to mammals. In humans, they play important roles in many 
physiological processes and in drug pharmacokinetics, pharmacody-
namics, and drug-to-drug interactions of many currently used medi-
cations in oncology, emergency medicine, critical care and general 
practice6,7. Inhibition of these transporters has been correlated with 
clinically relevant metabolic disorders, drug overdosing, and drug 
toxicity7. On the other hand, their overexpression can lead to treat-
ment failure due to enhanced drug cell clearance and increased drug 
excretion from the body7. Multi-drug resistance-associated protein 
2 (MRP2) is a well-studied representative of the ABC transporters 
family, by which transport of glucuronide, sulphate and gluthatione-
conjugated drugs is made against a concentration gradient requiring 
adenosine-tri-phosphate (ATP) hydrolysis8.
Genetic expression of ABC transporters has been found to change 
in real and simulated microgravity conditions. Two independent 
studies evaluated gene expression pattern in two models of medi-
cally relevant species of microorganisms (Salmonella sp. and Can-
dida sp.) and found upregulation of certain ABC transporters genes 
during short duration spaceflight missions9,10. Similarly, results 
from a microgravity simulation study showed that significant vari-
ation of certain ABC transporter levels could be found in the liver 
and kidneys of a murine model11. These changes could lead to a 
modified antimicrobial susceptibility in microgravity and to differ-
ent pharmacokinetic characteristics of medications during space-
flight. Furthermore, recent reports suggest that microgravity can 
modify the activity of certain important cell components12–14, espe-
cially transmembrane proteins and ion channels15–17 with structural 
and functional similarities to ABC transporters. Changes in ABC 
transporters activity could lead to clinically significant metabolic 
disorders and potentially dangerous undesired pharmacological 
effects during spaceflight. However, there is no current technology 
that permits a functional evaluation of these cellular components in 
microgravity. Therefore, we developed a new approach combining 
the use of a currently available commercial assay, a high precision 
electromechanical system and an enhanced drug detection protocol 
to evaluate ABC transporters activity in microgravity conditions. A 
validation study of this new biotechnological approach is presented.
Glossary
Microgravity: A condition in which there is very little net gravita-
tional force, as of a free-falling object, an orbit, or interstellar space. 
In this text microgravity, weightlessness and zero gravity (0g) are 
considered equivalents.
Parabolic flight/parabolic flight campaign: To create a weightless 
environment, an especially prepared airplane flies in a long para-
bolic arc, in which two 2g periods are experienced while ascending 
(injection phase) and recovering (pull out phase) from the manoeu-
vre. In between these two periods, the aircraft enters into a free 
falling state, lasting approximately 22s, in which microgravity is 
obtained inside the cabin. A regular parabolic flight consists of 30 
parabolas with a number of breaks. A parabolic flight campaign 
consists of three flights.
Methods
This study was performed during the 51st European Space Agency 
(ESA) parabolic flight campaign, under the auspices of the “Fly 
your thesis” programme, and was developed following the speci-
fications and experimental requirements of ESA/Novespace para-
bolic flight campaigns18.
Samples and procedures
A modified, validated and commercial Vesicular Transport Assay® 
(Solvo Biotechnology, Hungary) was used to evaluate MRP2 
transport activity of estradiol 17-β-glucuronide (E17βG) in micro-
gravity during parabolic flights. A short overview of this assay 
is provided hereinafter and additional information can be found 
at the producer’s website (www.solvo.hu). Recombinant baculo-
virus infected insect cells (Sf9 cells) are used to produce micro-
scopic vesicles containing at least 12–15% of the selected human 
transporter protein following a standardized and validated produc-
tion protocol owned by the producer7. Vesicles are built allowing 
transport towards the interior of the vesicle. Once a reaction is 
triggered, the substrate (E17βG) is transported into vesicles and 
retained. Vesicles are filtrated using a fiberglass Milipore filter 
(< 1μm pore size) and eluted with pure methanol to retrieve sub-
strate, which is later analysed. In the Vesicular Transport Assay®, 
a base sample suspension is produced containing selected vesicles 
(50 μg of pure MRP2 transporter per sample) and an assay mix 
composed by E17βG, co-transporters and ions. Concentrations of 
the assay mix and vesicle quantities followed the instructions con-
tained in the protocol provided by the vesicle producer, however 
volumes were adjusted to adapt to minimum volume requirements 
of our automated electromechanical system and to reduce the 
error induced by mechanical actuators. By modifying the afore-
mentioned base suspension, four different groups of samples were 
generated to evaluate four different assay conditions as recom-
mended by the producer19. MRP2+ samples, containing a fully 
functional MRP2 transporter, were generated in order to evaluate 
the full transport capabilities of the transporter. NoATP samples 
were generated by using the same composition of MRP2+ sam-
ples but an ATP-free solution was injected instead at the moment 
of reaction start. These groups of samples permitted the evalua-
tion of ATP-independent transport activity, known to be present in 
the ABC transporters family. Following vesicle producer recom-
mendations, we also generated an additional group of samples to 
which benzbromarone 7.5 mM (BZM - specific non-competitive 
inhibitor) was added. In this set of samples, pharmacological 
inhibition capabilities in microgravity could be assessed. Finally, 
MRPdef negative control samples were generated from vesicles 
with mutated MRP-like transporters. These vesicles are provided 
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by the producer and present no active transport capabilities. 
Therefore, they permit evaluation of simple diffusion of substrate 
across membranes. These samples were used as negative controls 
for transporter activity measurements (see supplementary mate-
rial Appendix 1. Chemical products for a more detailed sample 
composition description). Confirmation of transporter activation 
requires the detection of net E17βG quantities in activated samples 
(MRP2+, noATP and BZM samples). Therefore, the signal from 
MRPdef samples was subtracted from the actual signal in each 
group of samples to obtain net transport activity. We performed 
a preliminary evaluation of the assay, which showed fast initial 
reaction speeds with most of E17βG being transported within 
few seconds. Samples were prepared in small syringes (Becton, 
Dickinson and Company, New Jersey, USA) containing 360 μl 
of the assay suspension (vesicles + assay mix), frozen immedi-
ately at -80°C and transported in dry ice to the parabolic flight 
campaign site. During the parabolic flight, the samples were kept 
in certified cold containers at 2–6°C before being used. The first 
five parabolas of each flight were excluded in order for the inves-
tigator to acclimatize to microgravity. The reaction was manually 
triggered 1s after the 6th parabola injection phase by a precise 
servo-mechanic injection of 250 μl 0.2M ATP mix or ATP-free 
buffer depending on the sample group (MRP2+, BZM and MRP-
def samples vs. noATP samples). The reaction was stopped auto-
matically inducing a drastic temperature reduction and substrate 
dilution by applying 1.5 ml of washing mix at 2–6°C after 19s, 
still in microgravity. This procedure was repeated identically for 
each parabolic manoeuvre. Washing mix composition followed 
standard protocol specifications by the vesicle producer but vol-
umes were adjusted to adapt to minimum volume requirements of 
our automated electromechanical system and to reduce the error 
induced by mechanical actuators. E17βG-filled vesicles were 
recovered by Millipore fibreglass filtration. Once on ground, pure 
methanol elution was performed for E17βG recovery and stabili-
zation before transport. Standard Escherichia coli glucuronidase 
enzymatic reaction was later required for glucuronide removal 
from estradiol. Final estradiol concentration was measured by gas 
chromatography coupled to a mass spectrometry detection system 
(6890-GC/5973-MSD, Agilent Technologies, California, USA) 
using a validated methodology20. Reference experiments were 
repeated on ground in 1g conditions using the same equipment, 
materials and procedures as those used during parabolic flights. 
The time lapse between sample stabilization with methanol and 
analysis was comparable in both cases. Sample analysis was per-
formed using the same laboratory equipment and procedures. 
Results from 1g on ground reference experiments were compared 
with those obtained in microgravity conditions.
In order to evaluate vesicle microscopic structural integrity after 
gravitational stress, vesicles were exposed to 2g centrifugal forces 
in 60 consecutive 30s periods simulating a parabolic flight. Vesicles 
were compared to non-centrifuged controls at 200× under meth-
ylene blue tincture by experienced anatomo-pathologists (Pathol-
ogy Department, Corporació Sanitària Universitària Parc Taulí. 
Sabadell, Spain). Qualitative analysis of shape and mean size 
estimation of vesicles was performed by experienced anathomo-
pathologists, as well as a semi-quantitative vesicle number estima-
tion using multiple 1 mm2 sector partial counting method.
Equipment
An electro-mechanical engineering system was especially designed 
to undertake the required procedures in microgravity following the 
design and safety specifications for parabolic flights (Figure 1 & 
Figure 2). Four experimentation units composed the prototype, one 
Figure 1. Main experimental rack. The designed electromechanical system was composed of three racks. In this figure a scheme of the main 
rack is presented, containing the four experimentation units. One of the four experimentation units is highlighted with a dashed line. Several 
electrical holes permitted connection to all electrical components in the main rack (sensors, actuators, linear engines, resistances). One ATP-WB 
hole permitted access to liquid conductions transporting ATP and Wash Buffer to each experimentation units. Lengths are expressed in mm.
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Figure 2. Final prototype configuration. This picture shows the final configuration of the experiment on board the parabolic aircraft. The 
three racks presented were, from left to right: storage rack, main rack, fluids and control rack. All principal electric components were placed in 
a sealed fire-proof cabinet underneath the main rack to protect the equipment from water contact in case of failure of the containment system.
per each specific group of samples. Accurate fluid displacement 
was achieved implementing high precision component manufac-
turing and accurate linear engines (Schneider Electric, France). 
These engines presented 0.05 mm of displacement error, which 
represented a calculated 16 μl fluid displacement error (< 10% 
in our experimental setup). Sample temperature was strictly con-
trolled using a dedicated thermal control system, which consisted 
of four preheating chambers to raise the sample temperature from 
2–6°C to 37°C and four reaction chambers to maintain the tem-
perature at 37.3°C during the reaction. In order to protect the vesi-
cle integrity, 45°C was established as the maximum permissible 
temperature at syringe wall in preheating chambers given syringe 
radius and its thermal conductivity. Several temperature probes 
feedback a central computer, which maintained the temperatures at 
the required levels (Minco, Minneapolis, USA; TC-Direct, Madrid, 
Spain). This system also enabled cold storage of ATP and washing 
mix at 2–6°C in two certified isothermal boxes (Tecnisample, 
Barcelona, Spain). All procedures were controlled by an electrical 
and control system, which provided electrical power, actuator control, 
synchronization, monitoring, logging and a user-friendly interface 
(Telemecanique, France) (see supplementary material Appendix 2. 
List of Components for a more detailed description of equipment 
and components used).
Statistical analysis
Results were analysed using SPSS v19.0 (International Business 
Machines, New York, United States of America). ANOVA test for 
multiple variable comparisons was performed to confirm differ-
ences in raw E17βG signal between the four sample groups in each 
gravitational condition. Bilateral Dunnett t post-hoc test was later 
used for comparing sample groups with MRPdef controls to con-
firm transporter activation. Provided equality of variances could not 
be assured and unbalanced size of groups being compared, non-
parametric Mann-Witney U test was used to evaluate the differences 
between microgravity and 1g on ground samples. Statistical signifi-
cance threshold was established at p < 0.05 bilaterally in all cases.
Results
All four different assays presented expected E17βG signal profile in 
microgravity and on ground 1g conditions (Table 1), being MRP2+ 
samples the most active and MRPdef the less active group of sam-
ples in all gravitational conditions. The ANOVA test revealed statis-
tically significant signal differences between sample groups in each 
gravitational condition (on ground F = 4.95, p = 0.005 and micro-
gravity F = 13.45, p < 0.001) and post-hoc Dunnett t test confirmed 
statistically significant differences between MRP2+ and MRPdef in 
both microgravity and 1g conditions (Table 2). These results con-
firmed activation of the transporter in MRP2+ samples. MRP2 net 
transport activity of 1g on ground samples laid within commercial 
transport standards (4.61 ng in a range of 3.7 – 7.4 ng of E17βG in 
our experimental configuration), conversely microgravity samples 
suffered a 19-fold activity reduction with statistically significant 
differences of E17βG transported in all cases. The Mean activity 
differences between microgravity and 1g on ground samples were 
10.3 ng of E17βG in MRP2+ samples (Mann-Witney U < 0.001; 
p < 0.001; CI 95% = 7.4 – 13.2 ng E17βG), 5.95 ng of E17βG in 
MRPdef samples (Mann-Witney U < 0.001; p < 0.001; CI 95% = 
4 – 7.9 ng E17βG), 7.65 ng of E17βG in noATP samples (Mann-
Witney U < 0.001; p < 0.001; CI 95% = 6.14 – 9.16 ng E17βG) and 
9.12 ng of E17βG in BZM samples (Mann-Witney U < 0.001; p < 
0.001; CI 95% = 7.9 – 10.3 ng E17βG).
The use of consecutive 2g periods in order to simulate the effects 
of hypergravity present during a parabolic flight did not show 
differences in shape, size or number of vesicles between centri-
fuged vesicles and control samples. Aggregation of vesicles was 
not observed, neither macroscopically nor microscopically dur-
ing this simulation. The thermal control system implemented in 
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our prototype maintained the temperature of reaction chambers at 
37.25°C (CI 95%: 37.14 – 37.34°C) during the whole duration of 
experiments and kept the sample syringe wall temperature below 
45°C in preheating chambers in all cases.
Dataset 1. Data of active transmembrane drug transport in 
microgravity
http://dx.doi.org/10.5256/f1000research.4909.d34169
Results from both microgravity and 1g on-ground experiments are 
presented (labelled _0g and _1g). In each gravitational condition 
four different assays were performed: fully activated transporter or 
“MRP2+”, simple diffusion/control or “MRPdef”, ATP-independent 
transport or “noATP”, BZM inhibition assay samples or “BZM”.
Discussion
To our knowledge, this is the first validation study of a biotechnolog-
ical approach aimed at evaluating human ABC transporters-medi-
ated active transmembrane transport capabilities in microgravity. 
Despite the high signal variability expected, the precision attained 
by our electromechanical system and the enhanced sensibility of 
the detection protocol used, enabled us to detect net MRP2 trans-
port activity in the short microgravity periods provided by parabolic 
flights. Furthermore, activation profile and signal levels detected in 
1g on ground samples laid within expected commercial standards, 
confirming the validity of the equipment and procedures used.
The results obtained in microgravity samples showed a signifi-
cant reduction in MRP2 transport activity, when compared to on 
ground 1g controls, but presented a comparable activation profile. 
In order to ensure reliability of these findings, vesicle stability dur-
ing a parabolic flight was assessed on ground. Simulations revealed 
that vesicle microscopic structure could remain stable during para-
bolic manoeuvres, in spite of repeated hypergravity periods. Pro-
vided that materials, equipment, procedures and transportation 
means were equal for all samples in all gravitational conditions, 
we hypothesized that gravitational stress during parabolic flights 
may have exerted an effect upon the vesicle membrane or the trans-
porter, preventing proper transport or retention of E17βG. How-
ever, such modification should occur at an ultra-structural level, out 
of reach of our microscopic evaluation. Unfortunately, given the 
lack of similar research precedents, an ultra-structural evaluation of 
samples was not planned and was not possible after analysis, since 
all microgravity samples had been eluted to retrieve E17βG. There-
fore, the results of the present evaluation cannot provide a definitive 
explanation of the effect of microgravity upon ABC transporters-
mediated active transmembrane transport. Notwithstanding the 
aforementioned limitation, we tried to elaborate a plausible hypoth-
esis to explain the present observations.
Compelling evidence indicates that gravity is able to affect cellular 
and even molecular interactions in numerous life forms, such as 
in certain protozoa12,14, bacteria15, plant cells13,16,17 or mammals21–23. 
Enzymes from the cell membrane24, cytoskeleton25, cytosol26 and 
nucleus24 have been found to be sensible to gravitational changes. 
In principle, gravity is a weaker force compared to intermolecular 
bonds, polar-apolar interactions and van der Waals forces, there-
fore it is not clear yet how gravity could affect enzymatic reactions. 
However, changes in polar-apolar interactions and conformational 
changes of lipid structures occurring in microgravity could explain 
some observations24,25. Structures such as ion channels and trans-
membrane signalling systems can be significantly affected by 
changes in physicochemical properties of the lipid bi-layer cell 
membrane. Similarly, the mechanism of action of ABC transporters, 
although still not fully unveiled, is highly dependent on transporter-
membrane interactions28, which play a principal role in transporter 
stabilization and substrate recognition. Interestingly, we were able 
to demonstrate a reduction of the signal detected in MRPdef con-
trols, where only simple diffusion of substrate was possible. This 
finding could be explained by an impeded E17βG diffusion into 
vesicles, or by an increase in membrane permeability in micrograv-
ity, which would lead to increased E17βG leakage. In any case, the 
present observations are indicative of important structural changes 
in the lipid bi-layer in microgravity, which could be induced by 
Table 1. Detected E17βG signal in microgravity and 
1g conditions.
Sample n Mean* SD %† 
MRP2+ 26 0.49 0.17 100
MRPdef 31 0.25 0.12 51
noATP 25 0.29 0.14 60
BZM 24 0.27 0.20 54
MRP2+ 10 10.8 4.08 100
MRPdef 12 6.20 3.08 57
noATP 11 7.95 2.25 73
BZM 9 9.38 1.59 86
MRP2+: fully activated MRP2 transporter. MRPdef: MRP-like 
defective transporter. noATP: without ATP. BZM: Inhibition 
by benzbromarone. * Mean E17βG signal in nanograms. † 
Percentage of activity.
m
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Table 2. Net E17βG transport activity.
Mean 
difference*
Dunnett t 
p CI 95%
MRP2+ 0.24 < 0.001† 0.14 – 0.34
noATP 0.05 0.565 -0.05 – 0.14
BZM 0.02 0.952 -0.08 – 0.12
MRP2+ 4.61 0.002† 1.54 – 7.69
noATP 1.75 0.364 -1.25 – 4.74
BZM 3.18 0.049† 0.01 – 6.35
MRP2+: fully activated MRP2 transporter. MRPdef: MRP-like defective 
transporter. noATP: without ATP. BZM: Inhibition by benzbromarone. CI 
95%: confidence interval 95%
* Mean difference is obtained by subtracting MRPdef signal from the 
signal detected in each group of samples. Net E17βG transported in 
nanograms.
†Denotes statistically significant
m
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1g
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n 
gr
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modified polar-apolar interactions of lipid structures in micrograv-
ity, as suggested elsewhere28. In this context, the interaction of ABC 
transporters with the membrane, substrate recognition capabilities 
and transporter activation could become significantly affected with 
the potential for relevant biological, physiological and medical con-
sequences in microgravity. However, additional research is required 
to confirm the present hypothesis.
There are many potential applications of the presented technology, 
which can benefit both space and terrestrial medicine. Insufficient 
information exists on drug effects in space4,5 and is often based in 
very reduced observational studies30 or in animal models31. While 
clinical experience throughout spaceflight history has shown no crit-
ical metabolic alterations in astronauts, few medications have been 
studied from a pharmacological point of view in space. A reduc-
tion of transmembrane drug transport capabilities in microgravity 
could lead to drug accumulation and potentially toxic effects during 
spaceflight. However an increase in membrane permeability would 
lead to an enhanced drug clearance, increased absorption and sig-
nificant changes in pharmacological proprieties of drugs. Although 
not conclusive, our results warrant additional and thorough evalua-
tion of this and other human drug transportation systems in a more 
stable microgravity platform. To this end, this study describes a new 
method, based on in vitro analysis of human drug transmembrane 
transport capabilities, by which an approximation to drug effects 
in microgravity can be made. Similarly, reduced activity of certain 
ABC transporters has been associated with a number of serious 
medical conditions on Earth. On the other hand, enhanced activity 
of ABC transporters can decrease intestinal drug absorption, facili-
tate hepatic and renal drug excretion, modify drug distribution, and 
limit drug penetration to certain body tissues. These transporters are 
known to be responsible for a significant portion of the variability in 
treatment response to certain drugs used in emergency and critical 
care medicine6–8 and can cause multidrug resistance in a number of 
solid and hematological neoplasias, where overexpression of cer-
tain ABC transporters is present6,7. Further research derived from 
this study may help elucidate the intricate mechanism of action 
of ABC transporters and provide new information for developing 
more effective treatments for oncology and other medical speciali-
ties based on microgravity effects upon these transporters.
There are several limitations in this study. First, we designed a 
novel electromechanical system to allow the required biochemical 
reactions to be undertaken precisely and automatically in parabolic 
flights. This equipment had never been tested before in such con-
ditions. However, results from 1g on ground control samples laid 
within commercial transport standards, proving functionality and 
validity of the research equipment and protocols used. Additionally, 
MRP2 net E17βG transport activity in microgravity fell within the 
detection range of our enhanced detection method, which confirmed 
that the required sensitivity was reached. Second, as previously 
addressed by Macarrone et al.28, “microgravity is likely to favour 
the dispersion in water of less dense molecules such as lipids and 
the opposite is observed in hypergravity”. The contact surface avail-
able for ABC transporter exposition to drug-rich medium would be 
reduced, and transport capability would consequently be dimin-
ished, if vesicles precipitated during 2g phases in parabolic flights. 
Furthermore, vesicle structural integrity has never been evaluated 
in variable gravitational conditions. Nevertheless, no macroscopic 
precipitation of samples was observed in-flight due to combined 
effects of aircraft vibration and the ATP turbulent injection jet. 
On-ground hypergravity simulation data suggested that vesicles 
remained stable and did not aggregate after repeated 2g periods. 
However ultrastructural alterations affecting the membrane or the 
transporter could still be possible and were not evaluated. Further 
research should focus on performing a detailed ultra-structural eval-
uation of vesicles and transporters in a more stable microgravity 
platform and use whole human cells to provide a more conclusive 
answer on the potential physiological and clinical effects of our 
findings. Other factors were also considered as possible disruptors 
of results and were evaluated. The temperature was strictly main-
tained within a narrow margin during experiments but aircraft pres-
sure was reduced in flight (800 hPa in flight). However, pressure 
variations were not expected to cause any modification in sample 
composition nor in transport activity in our experimental setup.
In conclusion, we validated a new methodology for evaluating ABC 
transporters activity in microgravity during parabolic flights. Our 
results demonstrated that despite time constrains, the combination 
of an adapted commercial assay, a highly accurate electromechani-
cal system and an enhanced drug detection protocol can provide 
enough accuracy, reproducibility and sensitivity to detect transport 
activity in microgravity. A significant decrease in transport activity 
of fully activated samples and a reduction of signal detected in neg-
ative controls could be observed in microgravity. While the present 
results are insufficient for drawing conclusive explanations to these 
observations, we hypothesize that altered polar-apolar interac-
tions induced by gravitational stress during parabolic manoeuvres 
affected vesicle’s lipid bi-layer membrane, eventually changing its 
physicochemical properties, limited simple diffusion phenomena 
and impaired transporter - membrane interaction. However, alter-
native explanations are possible. Therefore, additional studies will 
be required to assess membrane and transporter ultra-structures in 
microgravity, and to confirm these results. The novel methodologi-
cal approach presented here opens new and interesting research lines 
in biology, microbiology and human physiology with the potential 
for significant benefits for both space and terrestrial medicine.
Data availability
Dataset 1. Data of active transmembrane drug transport in micro-
gravity, 10.5256/f1000research.4909.d3416932
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Products used for in-flight operations
1.7M Tris (Tris[hydroxymethyl] aminomethane) Water based Dilution
0.1 M MOPS-Tris (Solution)
300 mM Glutathione (GSH)
DMSO. Dimethyl sulfoxide
7.5 mM E17βG in DMSO
0.2 M Mg-ATP (ATP, MgCl2, Tris)
0’1M MgCl2 
0.14 M KCl
1 M KCl
7’5 mM Benzbromarone in DMSO
MRP2 Vesicles
Assay Mix (solution): 0.1M MOPS-Tri (50% of the solution), 0.14M KCl (50% of the 
solution), 0.1 MgCl2 (<1% of the solution)
Solutions used for in-flight operations
Washing Mix: 0.1 MOPS-Tris (40% of the solution), 1M KCl (2,5% of the solution), 
Milli-Q Water (47,5% of the solution)
Syringes: MRP2/Control vesicles (<1%) + Assay Mix (97%) + Benzbromarone (1%) + 
GSH (<1%) + DMSO (1%) + Estradiol (<1%)
Assay Mix (solution): 0.1M MOPS-Tris (50% of the solution), 0.14M KCl (50% of 
the solution), 0.1 MgCl2 (<1% of the solution)
0.2 M Mg-ATP (ATP, MgCl2, Tris)
Appendix
Chemical products
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Fluid System 
Id Company Ref. Description
Jx BD 300910 Reaction syringe (3 ml)
J1 BD 300910 Reaction syringe (3 ml)
J2 BD 300912 ATP/Assay Mix syringe (60 ml)
J3 BD 300865 Washing mix syringe (60 ml)
J4 BD 300865 Washing mix syringe (60 ml)
J5 BD 300865 Waste syringe (60 ml)
J6 BD 300865 Waste syringe (60 ml)
J7 BD 300865 Waste syringe (60 ml)
Anti-leak diaphragm 
valve BD 385100 Anti-leak valve
V1 BD 394600 3 ways valve
V2 BD 394600 3 ways valve
Tube PVC BD 397251 PVC line extension
BD: Becton, Dickinson and Company
Heating System 
Id Company Ref. Description
TMP1-8 TC-Direct 410-215 Temperature probe
R1-4 Minco HK5407R98.1L12A Resistance heating
R5-8 Minco HK5591R91.4L12A Resistance heating
Minco #20 TAPE 6FT Self-fusing silicone tape
FU1-4 RS components 176-9132 Resettable thermal fuse 84°C
FU5-8 RS components 176-9148 Resettable thermal fuse 72°C
Cooling System 
Id Company Ref. Description
Polyurethane box Tecnisample ISOPUR 13 Contains 1 ATP syringe and 8 Washing mix syringes
Polystyrene box Tecnisample N/A Contains 100 new sample syringes
Cold Accumulators Tecnisample N/A Rigid plastic water accumulators
Containment System 
Id Company Ref. Description
PMAFLEX tube PMA AG CYLG-48B
Tube which guarantees no leaks 
and two isolation level 
between ATP+WB box and 
polycarbonate sealed box.
Connector PMA AG BVID-M508GT
Accessory to connect PMAFLEX 
tube with ATP+WB box and 
polycarbonate sealed box.
Connector PMA AG GMN-M50 Nut of BVID-M508GT
New syringes box Peli 0340-001-110-E01 Case with a 67 IP protection level.
Used syringes box Peli 1450-001-110-E01 Case with a 67 IP protection level.
Used filters box Peli 1450-001-110-E01 Case with a 67 IP protection level.
ATP+WB box Peli 0340-001-110-E01 Case with a 67 IP protection level.
List of components:
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Electrical System 
Id Company Ref. Description
QS1 Telemecanique VCF01 Isolating switch 20A
QF1 Merlin Guerin C60N-11933 General breaker switch 2 Phases 7,5A
F1 Merlin Guerin ID23523 General dif. switch 2 Phases 25A 30mA
QF2-14 Merlin Guerin DPN-21555 Breaker switch 1 Phases 6A
FA1 Telemecanique ABL-8FEQ24200 Power unit 20A 24Vdc
PT1 Telemecanique XBT-GT4330 Touch screen
PLC 1 Telemecanique BMX-XBP0800 Rack 8 positions
Telemecanique ABE7 CPA412 Fast connector
Telemecanique ABE7 H16R20 Fast connector
Telemecanique ABE7 R16T212 Fast connector
Telemecanique BMX-CPS2000 Power unit CPU 20W
Telemecanique BMX-P342010 CPU
Telemecanique BMX-DDI3202 Digital in card
Telemecanique BMX-DDO3202 Digital out card
Telemecanique BMX-DDO3202 Digital out card
Telemecanique BMX-ART0414 Thermocouple input card
Telemecanique BMX-ART0414 Thermocouple input card
SBE Telemecanique XB5-AS8445 General Emergency button
SB1 Telemecanique XB5-AA42 Push Rearmament
KA1 Telemecanique LC1DT20P7 Power relay (220VAC)
MLIN1 Schneider SER-36103L75 Linear actuator
MLIN2 Schneider SER-36103L75 Linear actuator
MLIN3 Schneider SER-36103L75 Linear actuator
MLIN4 Schneider SER-36103L75 Linear actuator
LXM05.1 Schneider LXM05AD10M2 Servodrivers
LXM05.2 Schneider LXM05AD10M2 Servodrivers
LXM05.3 Schneider LXM05AD10M2 Servodrivers
LXM05.4 Schneider LXM05AD10M2 Servodrivers
ST1 Schneider BRS364H Stepper motor
CST1 Schneider SD3 15 Controller stepper motor
ST2 Schneider BRS364H Stepper motor
CST2 Schneider SD3 15 Controller stepper motor
ST3 Schneider BRS364H Stepper motor
CST3 Schneider SD3 15 Controller stepper motor
ST4 Schneider BRS364H Stepper motor
CST4 Schneider SD3 15 Controller stepper motor
ST5 Schneider BRS364H Stepper motor
CST5 Schneider SD3 15 Controller stepper motor
ST6 Schneider BRS364H Stepper motor
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Id Company Ref. Description
CST6 Schneider SD3 15 Controller stepper motor
ST7 Schneider BRS364H Stepper motor
CST7 Schneider SD3 15 Controller stepper motor
ST8 Schneider BRS364H Stepper motor
CST8 Schneider SD3 15 Controller stepper motor
TMP1-8 TC-Direct 408–053 Temperature probe
R1-4 Minco HK5407R98.1L12A Heating resistance
R5-8 Minco HK5591R91.4L12A Heating resistance
E1-12 Schneider Xs1N08PA349 Sensors 10A38VCC 2MM
Weidmüller WDK 2.5 Terminal block
Himel PLA-1573KT Electrical box
Himel PMR157 Electrical plate
Himel S27 DL/24 Auxiliar electrical box
Himel PF-27 Fixing to auxiliar electrical box
Himel IBS 1912/8 Terminal electrical box (*2)
Himel PMDP 2015 Terminal electrical plate (*2)
PC BENQ R53U-S07-PM740C8UGH6 Laptop
Himel VF38 Ventilator (Refrigeration unit)
BTN Telemecanique XB4-BW33B5 Green light push button “START”
BTN Telemecanique XB4-BW36B5 Blue light push button “ARM”
BTN Telemecanique XB4-BW35B5 Yellow light push button “STOP”
BTN Telemecanique XB4-BW34B5 Red light push button “HALT”
PMA CYLG-29S Plastic tube
PMA BVID-M329GT Connector tube
PMA GMN-M32 Nut
PMA SVH-29-010 Clamps
INTERFLEX 012577 Gland
INTERFLEX 011277 Gland
UNEX 60.40.77 Gutters
UNEX 60.60.77 Gutters
ILME CNF16 CNM16 Harting connector
ILME MHO32L CHI32LS Harting connector
Schneider DF2 CN08 Fast fuse 8A
Schneider DF6 AB10 Carrier fuse
FU1-4 RS 176-9148 Resettable thermal fuse 84°C
FU5-8 RS 176-9132 Resettable thermal fuse 72°C
KA2-9 Finder Type 40.52 Relays
220V female plug
RS 327-131 220V male plug
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This paper is an interesting contribution to the study of membrane transporter activity in microgravity. The
authors discuss in detail the problems not addressed by the study, and important future studies for further
validation. This is an excellent addition to the literature, and should be indexed.
Introduction was a concise and accurate overview of ABC transporters and microgravity
simulations.
 
Good use of controls, including consideration of differential permeability of vesicles themselves
due to microgravity
 
No control with BZM/deformed MPR2 to see differences in noncompetitive inhibition (see if there’s
activity in negative control vesicles (MRP2def) to see if relevant, particularly for the point about
inherent changes in vesicle permeability mentioned in Discussion).
 
Vesicle integrity was confirmed with 2g on-ground simulated flight campaign study (why not just
run study at 1g alongside samples to eliminate confounding variables?). Also, is it apparent that the
2g on-ground study truly replicates the experimental flight campaign?
 
Table 2: NoATP mean diference, microgravity, is 0.04, not 0.05 (according to Table 1). Same
mistake with 1g on ground MRP2+, though this is most likely due to rounding.
 
Following Table 2’s purpose, comparing relative difference (dividing microgravity and 1g mean
differences by MRP2def) would have made data more comparable, given stark differences in
means presented in Table 1.
 
Data seem to have high variance, despite precision provided by the in-flight device. Comparison of
various flight results in groups would hint at potential time-based variance or subtle differences in
parabolic flight that could have contributed to these results (repeated flights, to achieve true
replicates over pseudoreplicates, could have also aided in this, though may be impractical given
predicted high cost of this single flight campaign).
 
No data presented on vesicle integrity outside of discussion in Results; even if not significant,
would have been useful.
 
It is not clear that microgravity causes an increase in vesicle permeability given the quite reduced
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It is not clear that microgravity causes an increase in vesicle permeability given the quite reduced
transport of E17BG in microgravity, as suggested in the discussion, though the ratio of E17BG
transport in microgravity is higher than that of 1g transport. Future studies looking into this would
be useful.
 
More information on parabolic flight campaign would have been useful, not only for reproducibility
but given the novelty of this procedure. 
 
Studying differential effects of microgravity on mammalian versus insect vesicles would be an
important follow-up investigation, as suggested by the authors.
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believe that it would be good to clarify how many parabolas were used for the tests.
Figures are ok, although figure 2 does not add much to the study itself, unless some explanation is
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Results
I believe that figures could show the microG changes better
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I think it should be 1G (not just in results but throughout the text), and then ground should be
deleted (it is a pleonasm in this case)
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It is very good, clear, and consistent
Conclusion
It could be shortened a bit.
It was very good to have considered and presented the limitations of the study.
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